Y
Yang Pu
Researcher at Peking Union Medical College
Publications - 9
Citations - 889
Yang Pu is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Immunotherapy & Acquired immune system. The author has an hindex of 6, co-authored 8 publications receiving 602 citations. Previous affiliations of Yang Pu include University of Texas Southwestern Medical Center & University of Chicago.
Papers
More filters
Journal ArticleDOI
CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
Xiaojuan Liu,Yang Pu,Kyle R. Cron,Liufu Deng,Justin Kline,William A. Frazier,Hairong Xu,Hua Peng,Yang Xin Fu,Yang Xin Fu,Meng Michelle Xu +10 more
TL;DR: It is revealed that the therapeutic effects of CD47 blockade depend on dendritic cell but not macrophage cross-priming of T cell responses, suggesting that T cell–mediated elimination of immunogenic tumors is driven by anti-CD47 treatment, further bridging the innate and adaptive responses.
Journal ArticleDOI
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling
Meng Michelle Xu,Yang Pu,Dali Han,Yaoyao Shi,Xuezhi Cao,Hua Liang,Xiang Chen,Xiao Dong Li,Liufu Deng,Zhijian J. Chen,Ralph R. Weichselbaum,Yang Xin Fu +11 more
TL;DR: DCs are specialized in sensing mtDNA after CD47 blockade through inhibiting uptaken DNA degradation in their phagosomes while macrophages rapidly degrade DNA, and it is suggested that the CD47‐SIRP&agr; axis is critical for DC‐driven antitumor immunity.
Journal ArticleDOI
Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse
Yang Pu,Meng Xu,Yong Liang,Kaiting Yang,Yajun Guo,Xuanming Yang,Yang Xin Fu,Yang Xin Fu,Yang Xin Fu +8 more
TL;DR: The authors characterized the mechanism of the immunosuppression and found that medical ADT interfered with initial T cell priming rather than reactivation and expansion, suggesting that careful regulation of timing and dose could improve the efficacy of this combination therapy.
Journal ArticleDOI
Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.
Shiyu Sun,Yueqi Cai,Tian-Zhang Song,Yang Pu,Lin Cheng,Hairong Xu,Jing Sun,Chaoyang Meng,Yifan Lin,Haibin Huang,Fang Zhao,Silin Zhang,Yu Gao,Jian-Bao Han,Xiao-Li Feng,Dan-Dan Yu,Yalan Zhu,Pu Gao,Haidong Tang,Jincun Zhao,Zheng Zhang,Jiaming Yang,Zhenxiang Hu,Yang Xin Fu,Yong-Tang Zheng,Hua Peng +25 more
TL;DR: In this article, an interferon-armed RBD dimerized by an immunoglobulin fragment (I-R-F) was developed to enhance antigen processing and cross-presentation in draining lymph nodes (DLNs).
Journal ArticleDOI
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
TL;DR: It is argued that significant progress for combined therapies will require a better understanding of the complex interactions between immune cells, the tumor, and the tumor microenvironment (TME) in different cancer settings.